LIVIVO - Search results -

Search results

Result 1 - 10 of total 190

Search options

Article ; Online: Real-World Clinical Studies to Understand the Current Status and Future Improvements of Pulmonary Rehabilitation in Chronic Lung Diseases.

Lee, Hyun / Moon, Ji-Yong / Min, Kyung Hoon

2024 Volume 165, Issue 4, Page(s) e125

MeSH term(s)	Humans ; Lung Diseases ; Pulmonary Disease, Chronic Obstructive/rehabilitation ; Quality of Life ; Exercise Tolerance
Language	English
Publishing date	2024-03-16
Publishing country	United States
Document type	Letter
ZDB-ID	1032552-9
ISSN	1931-3543 ; 0012-3692
ISSN (online)	1931-3543
ISSN	0012-3692
DOI	10.1016/j.chest.2023.10.045
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui III Zs.45: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 349: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Proposed Etiotypes for COPD: Controversial issues.

Kim, Sang Hyuk / Moon, Ji-Yong / Min, Kyung Hoon / Lee, Hyun

Tuberculosis and respiratory diseases

2024

Abstract: The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) revised the definition of chronic obstructive pulmonary disease (COPD) to broadly include a variety of etiologies. A new taxonomy, composed of etiotypes, aims to highlight the ... ...

Abstract	The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) revised the definition of chronic obstructive pulmonary disease (COPD) to broadly include a variety of etiologies. A new taxonomy, composed of etiotypes, aims to highlight the heterogeneity in causes and pathogenesis of COPD, allowing more personalized management strategies and emphasizing the need for targeted research to understand and manage COPD better. However, controversy arises with including some diseases under the umbrella term of COPD, as their clinical presentations and treatments differ from classical COPD, which is smoking-related. COPD due to infection (COPD-I) and COPD due to environmental exposure (COPD-P) are classifications within the new taxonomy. Some disease entities in these categories show distinct clinical features and may not benefit from conventional COPD treatments, raising questions about their classification as COPD subtypes. There is also controversy regarding whether bronchiectasis with airflow limitations should be classified as an etiotype of COPD. This article discusses controversial issues associated with the proposed etiotypes for COPD in terms of COPD-I, COPD-P, and bronchiectasis. While the updated COPD definition by GOLD 2023 is a major step towards recognizing the disease's complexity, it also raises questions about the classification of related respiratory conditions. This highlights the need for further research to improve our understanding and approach to COPD management.
Language	English
Publishing date	2024-02-06
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2161256-0
ISSN	1738-3536 ; 0378-0066
ISSN	1738-3536 ; 0378-0066
DOI	10.4046/trd.2023.0194
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5937: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia.

Kim, Bo-Guen / Kang, Danbee / Min, Kyung Hoon / Cho, Juhee / Jeon, Kyeongman

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 6

Abstract: Although cefepime and piperacillin/tazobactam are commonly prescribed for the treatment of hospital-acquired pneumonia (HAP), which one is the superior therapy remains unclear. Using Korean National Health Insurance Service data from January 2018 to ... ...

Abstract	Although cefepime and piperacillin/tazobactam are commonly prescribed for the treatment of hospital-acquired pneumonia (HAP), which one is the superior therapy remains unclear. Using Korean National Health Insurance Service data from January 2018 to December 2018, we compared the clinical outcomes of patients with HAP who were treated with cefepime and those treated with piperacillin/tazobactam. Data from 9955 adult patients with HAP, of whom 1502 (15%) received cefepime and 8453 (85%) received piperacillin/tazobactam, were retrieved for primary analysis. Tube feeding, suctioning, positioning care, and intensive care unit admission were more common among patients who received piperacillin/tazobactam. Treatment outcomes, including rates of in-hospital mortality, pneumonia-related readmission, and all-cause mortality within 6 months after discharge, were comparable between the two groups. In a subgroup analysis of data from patients who required tube feeding, the risk for in-hospital mortality was significantly higher among those who received cefepime (fully adjusted odds ratio, 1.43; 95% confidence interval, 1.04-1.97;
Language	English
Publishing date	2023-05-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12060984
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinical outcomes of fluoroquinolones combination therapy in patients with hospital-acquired pneumonia: a retrospective cohort study using national health insurance claims data in Korea.

Kim, Bo-Guen / Kang, Danbee / Min, Kyung Hoon / Cho, Juhee / Jeon, Kyeongman

Journal of thoracic disease

2023 Volume 15, Issue 12, Page(s) 6644–6650

Abstract: Background: Fluoroquinolones are one of the commonly used antibiotics for the initial empiric combination treatment. However, there is insufficient evidence to support the use of fluoroquinolones combination therapy for the treatment of hospital- ... ...

Abstract	Background: Fluoroquinolones are one of the commonly used antibiotics for the initial empiric combination treatment. However, there is insufficient evidence to support the use of fluoroquinolones combination therapy for the treatment of hospital-acquired pneumonia (HAP). This study aimed to evaluate the effectiveness of fluoroquinolones as part of the empiric combination therapy for HAP using national health insurance claims data in Korea. Methods: We compared the clinical outcomes of patients with HAP who received fluoroquinolones combination and those treated with cefepime or piperacillin/tazobactam monotherapy. The primary outcome was hospital mortality, and the secondary outcome was readmission caused by pneumonia as the primary cause of hospitalization within 7 days after discharge from index hospitalization. The association between the combination with fluoroquinolones and outcomes was evaluated with logistic regression analysis. Results: Among the 9,955 patients with HAP administered with cefepime or piperacillin/tazobactam, 4,918 (49%) received fluoroquinolones combination. During hospitalization, 1,059 (11%) patients with HAP died. Compared with the monotherapy group, the fluoroquinolones combination therapy group was associated with a higher mortality risk [adjusted odds ratio (OR), 1.30; 95% confidence interval (CI): 1.02-1.65]. After adjusting for potential confounding factors, the association remained significant in the non-high-risk HAP group (adjusted OR, 1.30; 95% CI: 1.02-1.66). Meanwhile, the mortality risk was similar between the fluoroquinolones combination therapy group and the monotherapy group of patients with high-risk HAP (adjusted OR, 0.99; 95% CI: 0.35-1.16). Among the patients alive and discharged (n=8,896), 152 (1.7%) were readmitted within 7 days after discharge. The fluoroquinolones combination therapy group was more likely to be readmitted because of pneumonia than the monotherapy group in patients with high-risk HAP (adjusted OR, 1.60; 95% CI: 1.04-2.47). Conclusions: Fluoroquinolones combined with β-lactams was prescribed in nearly half of patients with low-risk HAP, and it was associated with a higher mortality risk in real-world practice. However, it was not associated with hospital mortality even in patients with high-risk HAP.
Language	English
Publishing date	2023-12-18
Publishing country	China
Document type	Journal Article
ZDB-ID	2573571-8
ISSN	2077-6624 ; 2072-1439
ISSN (online)	2077-6624
ISSN	2072-1439
DOI	10.21037/jtd-23-787
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Both quality of life and exacerbation are important outcomes of work-related asthma.

Jang, Jong Geol / Lee, Hyun / Min, Kyung Hoon / Kim, Sang-Heon / Yoon, Ho Joo / Moon, Ji-Yong

The journal of allergy and clinical immunology. In practice

2024 Volume 12, Issue 3, Page(s) 803–804

MeSH term(s)	Humans ; Quality of Life ; Asthma/epidemiology ; Surveys and Questionnaires
Language	English
Publishing date	2024-02-24
Publishing country	United States
Document type	Letter
ZDB-ID	2843237-X
ISSN	2213-2201 ; 2213-2198
ISSN (online)	2213-2201
ISSN	2213-2198
DOI	10.1016/j.jaip.2023.12.044
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.

Kim, Jihyung / Im, Chang Gyun / Oh, Kyujin / Lee, Ji Min / Al-Rubaye, Fatimah / Min, Kyung Hoon

Journal of enzyme inhibition and medicinal chemistry

2024 Volume 39, Issue 1, Page(s) 2343350

Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. FGFR4 has been implicated in HCC progression, making it a promising therapeutic target. We introduce an approach for identifying novel FGFR4 inhibitors by sequentially adding ... ...

Abstract	Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. FGFR4 has been implicated in HCC progression, making it a promising therapeutic target. We introduce an approach for identifying novel FGFR4 inhibitors by sequentially adding fragments to a common warhead unit. This strategy resulted in the discovery of a potent inhibitor,
MeSH term(s)	Receptor, Fibroblast Growth Factor, Type 4/antagonists & inhibitors ; Receptor, Fibroblast Growth Factor, Type 4/metabolism ; Humans ; Structure-Activity Relationship ; Drug Discovery ; Molecular Structure ; Dose-Response Relationship, Drug ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/chemical synthesis ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/chemical synthesis ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/metabolism
Chemical Substances	Receptor, Fibroblast Growth Factor, Type 4 (EC 2.7.10.1) ; FGFR4 protein, human (EC 2.7.10.1) ; Protein Kinase Inhibitors ; Antineoplastic Agents
Language	English
Publishing date	2024-04-24
Publishing country	England
Document type	Journal Article
ZDB-ID	2082578-X
ISSN	1475-6374 ; 1475-6366
ISSN (online)	1475-6374
ISSN	1475-6366
DOI	10.1080/14756366.2024.2343350
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3004: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparative Analysis of Clinical Outcomes Using Propensity Score Matching: Coronavirus Disease 2019 vs. Seasonal Influenza in Korea.

Sim, Jae Kyeom / Lee, Hye Sun / Yang, Juyeon / Gwack, Jin / Kim, Bryan Inho / Cha, Jeong-Ok / Min, Kyung Hoon / Lee, Young Seok

Journal of Korean medical science

2024 Volume 39, Issue 14, Page(s) e128

Abstract: Background: The advent of the omicron variant and the formulation of diverse therapeutic strategies marked a new epoch in the realm of coronavirus disease 2019 (COVID-19). Studies have compared the clinical outcomes between COVID-19 and seasonal ... ...

Abstract	Background: The advent of the omicron variant and the formulation of diverse therapeutic strategies marked a new epoch in the realm of coronavirus disease 2019 (COVID-19). Studies have compared the clinical outcomes between COVID-19 and seasonal influenza, but such studies were conducted during the early stages of the pandemic when effective treatment strategies had not yet been developed, which limits the generalizability of the findings. Therefore, an updated evaluation of the comparative analysis of clinical outcomes between COVID-19 and seasonal influenza is requisite. Methods: This study used data from the severe acute respiratory infection surveillance system of South Korea. We extracted data for influenza patients who were infected between 2018 and 2019 and COVID-19 patients who were infected in 2021 (pre-omicron period) and 2022 (omicron period). Comparisons of outcomes were conducted among the pre-omicron, omicron, and influenza cohorts utilizing propensity score matching. The adjusted covariates in the propensity score matching included age, sex, smoking, and comorbidities. Results: The study incorporated 1,227 patients in the pre-omicron cohort, 1,948 patients in the omicron cohort, and 920 patients in the influenza cohort. Following propensity score matching, 491 patients were included in each respective group. Clinical presentations exhibited similarities between the pre-omicron and omicron cohorts; however, COVID-19 patients demonstrated a higher prevalence of dyspnea and pulmonary infiltrates compared to their influenza counterparts. Both COVID-19 groups exhibited higher in-hospital mortality and longer hospital length of stay than the influenza group. The omicron group showed no significant improvement in clinical outcomes compared to the pre-omicron group. Conclusion: The omicron group did not demonstrate better clinical outcomes than the pre-omicron group, and exhibited significant disease severity compared to the influenza group. Considering the likely persistence of COVID-19 infections, it is imperative to sustain comprehensive studies and ongoing policy support for the virus to enhance the prognosis for individuals affected by COVID-19.
MeSH term(s)	Humans ; Influenza, Human/diagnosis ; Influenza, Human/epidemiology ; COVID-19/epidemiology ; Propensity Score ; Seasons ; SARS-CoV-2 ; Republic of Korea/epidemiology
Language	English
Publishing date	2024-04-15
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	639262-3
ISSN	1598-6357 ; 1011-8934
ISSN (online)	1598-6357
ISSN	1011-8934
DOI	10.3346/jkms.2024.39.e128
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 3163: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease.

Joo, Hyonsoo / Park, Seoung Ju / Min, Kyung Hoon / Rhee, Chin Kook

BMC pulmonary medicine

2021 Volume 21, Issue 1, Page(s) 86

Abstract: Background: The role of interleukin (IL)-33 in patients with chronic obstructive pulmonary disease (COPD) has not been well elucidated. The aim of this study is to analyze the association between plasma IL-33 level and acute exacerbation of COPD.: ... ...

Abstract	Background: The role of interleukin (IL)-33 in patients with chronic obstructive pulmonary disease (COPD) has not been well elucidated. The aim of this study is to analyze the association between plasma IL-33 level and acute exacerbation of COPD. Methods: Plasma IL-33 was measured in 62 COPD patients during their stable state. Patients were prospectively followed up for 1 year. The expression of IL-33 was measured in lung tissue obtained from 38 patients who underwent surgery. Results: The number of exacerbations was significantly higher in the high plasma IL-33 group compared with the low plasma IL-33 group. On Poisson regression analysis, high plasma IL-33 was associated with increased risk of exacerbation (incidence rate ratio = 2.166, P = 0.043). The expression of IL-33 in the lung was higher in COPD patients than in controls. The expression of IL-33 was significantly correlated with smoking pack years (R = 0.45, P < 0.01) and Forced expiratory volume in 1 s (%) (R = - 0.58, P < 0.01). Conclusion: The plasma level of IL-33 in patients with COPD was significantly associated with the risk of exacerbation in prospective follow up. The expression of IL-33 in the lung was positively correlated with smoking and negatively correlated with lung function.
MeSH term(s)	Aged ; Biomarkers/analysis ; Case-Control Studies ; Disease Progression ; Female ; Forced Expiratory Volume ; Humans ; Interleukin-33/blood ; Lung/metabolism ; Lung/pathology ; Male ; Middle Aged ; Prospective Studies ; Pulmonary Disease, Chronic Obstructive/blood ; Smoking/adverse effects
Chemical Substances	Biomarkers ; Interleukin-33
Language	English
Publishing date	2021-03-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2059871-3
ISSN	1471-2466 ; 1471-2466
ISSN (online)	1471-2466
ISSN	1471-2466
DOI	10.1186/s12890-021-01423-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Correction to: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease.

Joo, Hyonsoo / Park, Seoung Ju / Min, Kyung Hoon / Rhee, Chin Kook

BMC pulmonary medicine

2021 Volume 21, Issue 1, Page(s) 337

Language	English
Publishing date	2021-10-29
Publishing country	England
Document type	Published Erratum
ZDB-ID	2059871-3
ISSN	1471-2466 ; 1471-2466
ISSN (online)	1471-2466
ISSN	1471-2466
DOI	10.1186/s12890-021-01703-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.

Kim, Heecheol / Kim, Minjung / Oh, Kyujin / Lee, Sohee / Lim, Sunyoung / Lee, Sangdon / Kim, Young Hoon / Suh, Kwee Hyun / Min, Kyung Hoon

European journal of medicinal chemistry

2023 Volume 258, Page(s) 115584

Abstract: G-protein-coupled receptor 119 (GPR119) has great potential as a therapeutic target for the treatment of type II diabetes. Novel thieno[3,2-d]pyrimidine derivatives were discovered as GPR119 agonists through a bioisosteric replacement strategy. The ... ...

Abstract	G-protein-coupled receptor 119 (GPR119) has great potential as a therapeutic target for the treatment of type II diabetes. Novel thieno[3,2-d]pyrimidine derivatives were discovered as GPR119 agonists through a bioisosteric replacement strategy. The sulfonylphenyl thieno[3,2-d] pyrimidine scaffold was introduced, and its derivatives exhibited potent agonistic activity for GPR119 in cell-based assays. The representative derivative 43 displayed excellent pharmacokinetic profiles in rodents and significantly improved glucose tolerance in vivo. In OGTT study, compound 43 reduced significantly blood glucose levels in both mice and rats.
MeSH term(s)	Rats ; Mice ; Animals ; Structure-Activity Relationship ; Diabetes Mellitus, Type 2/drug therapy ; Glucose Tolerance Test ; Receptors, G-Protein-Coupled/agonists ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Antihypertensive Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use
Chemical Substances	Receptors, G-Protein-Coupled ; Pyrimidines ; Antihypertensive Agents ; Hypoglycemic Agents ; GPR119 protein, rat
Language	English
Publishing date	2023-06-19
Publishing country	France
Document type	Journal Article
ZDB-ID	188597-2
ISSN	1768-3254 ; 0009-4374 ; 0223-5234
ISSN (online)	1768-3254
ISSN	0009-4374 ; 0223-5234
DOI	10.1016/j.ejmech.2023.115584
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 784: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito